View Financial HealthBioethics 配当と自社株買い配当金 基準チェック /06Bioethics配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Apr 01Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2025, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 15Bioethics, Ltd. announced delayed 10-Q filingOn 08/14/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jun 27SILQ Technologies Corporation entered into a non-binding letter of intent to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction.SILQ Technologies Corporation entered into a non-binding letter of intent to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction on June 18, 2024. All outstanding shares of SILQ would then be converted into shares of Bioethics common stock pursuant to the definitive merger agreement. Following the closing of the transaction, the parties’ current intention and expectation as set out in the Letter of Intent is that the stockholders of SILQ would own approximately 89% of the fully diluted total outstanding stock of Bioethics, and the stockholders of Bioethics immediately prior to the closing of the transaction, including all current stockholders and all shares to be issued prior to the closing as more fully described in the Letter of Intent, would own 11% of the total outstanding stock of Bioethics following the transaction. In connection with the proposed Merger, Bioethics has agreed to consummate a 1-for-2 reverse stock split. Prior to the proposed Merger, Bioethics intends to issue common or preferred stock convertible into common stock in order to raise money to pay down debt and incentivize and otherwise compensate Bioethics’ officers, directors and consultants, who have not received cash compensation for years. It is currently anticipated that following the closing of the proposed Merger, that there will be at least 50,450,000 shares of Bioethics common stock issued an outstanding. This anticipated post-transaction outstanding stock will include the current outstanding shares of Bioethics after a 1-for-2 reverse stock split, meaning that the ownership of Bioethics of the current Bioethics stockholders, exclusive of all shares to be issued between now and the closing of the transaction, as a percentage of all anticipated outstanding stock will be approximately 1% of all outstanding Bioethics stock following the closing of the transaction. The transaction is subject to due diligence review.お知らせ • May 17Bioethics, Ltd. announced delayed 10-Q filingOn 05/15/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 02Bioethics, Ltd. announced delayed annual 10-K filingOn 04/01/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2023, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 16Bioethics, Ltd. announced delayed 10-Q filingOn 05/15/2023, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 16Bioethics, Ltd. announced delayed 10-Q filingOn 08/15/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 17Bioethics, Ltd. announced delayed 10-Q filingOn 05/16/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 01Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Aug 17Bioethics, Ltd. announced delayed 10-Q filingOn 08/16/2021, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 18Bioethics, Ltd. announced delayed 10-Q filingOn 05/17/2021, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Apr 02Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2021, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 17Bioethics, Ltd. announced delayed 10-Q filingOn 11/16/2020, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 06XCR Diagnostics, Inc. entered into a non-binding term sheet to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction.XCR Diagnostics, Inc. entered into a non-binding term sheet to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction on July 29, 2020. Pursuant to the term sheet, Bioethics will issue 34.2 million shares of Bioethics common stock post one-for-ten reverse stock split. Bioethics and certain of its creditors and affiliates agree to settle down all the liabilities of Bioethics except for $0.2 million. Post completion of the transaction and reverse stock split stockholders of XCR Diagnostics will have the majority share of Bioethics and XCR Diagnostics will become a financially consolidated subsidiary of Bioethics. Mark Scharmann and Elliott Taylor affiliates of Bioethics agrees to lock-up/leak-out agreement governing their shares. Bioethics will raise at least $0.3 million in a private placement within 90 days of closing. At closing, directors of Bioethics and XCR Diagnostics will resign and XCR Diagnostics will have the right to appoint all the directors of Bioethics. The initial directors are expected to be Mark Powelson, Mark Bagnall, Bruce Chafin, Chuck Morrison and Lynda Merrill. Board advisors will be Brian Caplin and Mark Scharmann. The transaction closing is subject to completion of due diligence of XCR Diagnostics by Bioethics, execution of reverse stock split, execution of definitive agreement document, obtaining necessary third party approvals, approval of the board of Bioethics and XCR Diagnostics, approval by the shareholders of Bioethics and XCR Diagnostics and the term sheet requires Bioethics to complete the private placement. The transaction is expected to close by or before August 28, 2020.決済の安定と成長配当データの取得安定した配当: BOTHの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: BOTHの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Bioethics 配当利回り対市場BOTH 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (BOTH)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Capital Markets)2.1%アナリスト予想 (BOTH) (最長3年)n/a注目すべき配当: BOTHは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: BOTHは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: BOTHの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: BOTHが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/02/10 16:38終値2025/11/13 00:00収益2024/12/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bioethics, Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 01Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2025, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 15Bioethics, Ltd. announced delayed 10-Q filingOn 08/14/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jun 27SILQ Technologies Corporation entered into a non-binding letter of intent to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction.SILQ Technologies Corporation entered into a non-binding letter of intent to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction on June 18, 2024. All outstanding shares of SILQ would then be converted into shares of Bioethics common stock pursuant to the definitive merger agreement. Following the closing of the transaction, the parties’ current intention and expectation as set out in the Letter of Intent is that the stockholders of SILQ would own approximately 89% of the fully diluted total outstanding stock of Bioethics, and the stockholders of Bioethics immediately prior to the closing of the transaction, including all current stockholders and all shares to be issued prior to the closing as more fully described in the Letter of Intent, would own 11% of the total outstanding stock of Bioethics following the transaction. In connection with the proposed Merger, Bioethics has agreed to consummate a 1-for-2 reverse stock split. Prior to the proposed Merger, Bioethics intends to issue common or preferred stock convertible into common stock in order to raise money to pay down debt and incentivize and otherwise compensate Bioethics’ officers, directors and consultants, who have not received cash compensation for years. It is currently anticipated that following the closing of the proposed Merger, that there will be at least 50,450,000 shares of Bioethics common stock issued an outstanding. This anticipated post-transaction outstanding stock will include the current outstanding shares of Bioethics after a 1-for-2 reverse stock split, meaning that the ownership of Bioethics of the current Bioethics stockholders, exclusive of all shares to be issued between now and the closing of the transaction, as a percentage of all anticipated outstanding stock will be approximately 1% of all outstanding Bioethics stock following the closing of the transaction. The transaction is subject to due diligence review.
お知らせ • May 17Bioethics, Ltd. announced delayed 10-Q filingOn 05/15/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 02Bioethics, Ltd. announced delayed annual 10-K filingOn 04/01/2024, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2023, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 16Bioethics, Ltd. announced delayed 10-Q filingOn 05/15/2023, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 15Bioethics, Ltd. announced delayed 10-Q filingOn 11/14/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 16Bioethics, Ltd. announced delayed 10-Q filingOn 08/15/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 17Bioethics, Ltd. announced delayed 10-Q filingOn 05/16/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 01Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2022, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Aug 17Bioethics, Ltd. announced delayed 10-Q filingOn 08/16/2021, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 18Bioethics, Ltd. announced delayed 10-Q filingOn 05/17/2021, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Apr 02Bioethics, Ltd. announced delayed annual 10-K filingOn 03/31/2021, Bioethics, Ltd. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 17Bioethics, Ltd. announced delayed 10-Q filingOn 11/16/2020, Bioethics, Ltd. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 06XCR Diagnostics, Inc. entered into a non-binding term sheet to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction.XCR Diagnostics, Inc. entered into a non-binding term sheet to acquire Bioethics, Ltd. (OTCPK:BOTH) in a reverse merger transaction on July 29, 2020. Pursuant to the term sheet, Bioethics will issue 34.2 million shares of Bioethics common stock post one-for-ten reverse stock split. Bioethics and certain of its creditors and affiliates agree to settle down all the liabilities of Bioethics except for $0.2 million. Post completion of the transaction and reverse stock split stockholders of XCR Diagnostics will have the majority share of Bioethics and XCR Diagnostics will become a financially consolidated subsidiary of Bioethics. Mark Scharmann and Elliott Taylor affiliates of Bioethics agrees to lock-up/leak-out agreement governing their shares. Bioethics will raise at least $0.3 million in a private placement within 90 days of closing. At closing, directors of Bioethics and XCR Diagnostics will resign and XCR Diagnostics will have the right to appoint all the directors of Bioethics. The initial directors are expected to be Mark Powelson, Mark Bagnall, Bruce Chafin, Chuck Morrison and Lynda Merrill. Board advisors will be Brian Caplin and Mark Scharmann. The transaction closing is subject to completion of due diligence of XCR Diagnostics by Bioethics, execution of reverse stock split, execution of definitive agreement document, obtaining necessary third party approvals, approval of the board of Bioethics and XCR Diagnostics, approval by the shareholders of Bioethics and XCR Diagnostics and the term sheet requires Bioethics to complete the private placement. The transaction is expected to close by or before August 28, 2020.